Abstract
Background: The IgE-mediated activation of effector cells and antigen-presenting cells through the high-affinity receptor for IgE (FcεRI) represents a key pathomechanism in type I allergy and many forms of asthma. Objective: We sought to establish an in vitro molecular model for the interaction of human FcεRI, IgE, and the corresponding allergen and to identify monoclonal anti-human IgE anti-bodies with a therapeutic profile different from previously established anti-IgE antibodies. Methods: Human FcεRI α chain, a human monoclonal allergen-specific IgE antibody (chimeric Bip 1), and the corresponding allergen, the major birch pollen allergen Bet v 1, were produced as recombinant proteins and analyzed by means of circular dichroism and native overlays, respectively. Using this molecular model, as well as negative stain immunoelectron microscopic analysis, and in vitro cultivated human basophils, we characterized mouse anti-human IgE antibodies. Results: We established a molecular model for the interaction of human IgE with FcεRI. Using this molecular model, we identified a nonanaphylactic anti-human IgE antibody fragment (Fab12), which blocked the IgE-FcεRI interaction and reacted with effector cell-bound IgE. Conclusion: Fab12 represents a candidate molecule for therapy of atopy and asthma because it can be used for the depletion of circulating IgE antibodies, as well as for the depletion of IgE-bearing cells.
| Original language | English |
|---|---|
| Pages (from-to) | 409-416 |
| Number of pages | 8 |
| Journal | Journal of Allergy and Clinical Immunology |
| Volume | 108 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 2001 |
| Externally published | Yes |
Fingerprint
Keywords
- Allergy
- Asthma
- Competitor
- FcεRI
- IgE
- Therapy
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
Cite this
A molecular model of type I allergy : Identification and characterization of a nonanaphylactic anti-human IgE antibody fragment that blocks the IgE-FcεRI interaction and reacts with receptor-bound IgE. / Laffer, Sylvia; Hogbom, Erik; Roux, Kenneth H.; Sperr, Wolfgang R.; Valent, Peter; Bankl, Hans C.; Vangelista, Luca; Kricek, Franz; Kraft, Dietrich; Grönlund, Hans; Valenta, Rudolf.
In: Journal of Allergy and Clinical Immunology, Vol. 108, No. 3, 2001, p. 409-416.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - A molecular model of type I allergy
T2 - Identification and characterization of a nonanaphylactic anti-human IgE antibody fragment that blocks the IgE-FcεRI interaction and reacts with receptor-bound IgE
AU - Laffer, Sylvia
AU - Hogbom, Erik
AU - Roux, Kenneth H.
AU - Sperr, Wolfgang R.
AU - Valent, Peter
AU - Bankl, Hans C.
AU - Vangelista, Luca
AU - Kricek, Franz
AU - Kraft, Dietrich
AU - Grönlund, Hans
AU - Valenta, Rudolf
PY - 2001
Y1 - 2001
N2 - Background: The IgE-mediated activation of effector cells and antigen-presenting cells through the high-affinity receptor for IgE (FcεRI) represents a key pathomechanism in type I allergy and many forms of asthma. Objective: We sought to establish an in vitro molecular model for the interaction of human FcεRI, IgE, and the corresponding allergen and to identify monoclonal anti-human IgE anti-bodies with a therapeutic profile different from previously established anti-IgE antibodies. Methods: Human FcεRI α chain, a human monoclonal allergen-specific IgE antibody (chimeric Bip 1), and the corresponding allergen, the major birch pollen allergen Bet v 1, were produced as recombinant proteins and analyzed by means of circular dichroism and native overlays, respectively. Using this molecular model, as well as negative stain immunoelectron microscopic analysis, and in vitro cultivated human basophils, we characterized mouse anti-human IgE antibodies. Results: We established a molecular model for the interaction of human IgE with FcεRI. Using this molecular model, we identified a nonanaphylactic anti-human IgE antibody fragment (Fab12), which blocked the IgE-FcεRI interaction and reacted with effector cell-bound IgE. Conclusion: Fab12 represents a candidate molecule for therapy of atopy and asthma because it can be used for the depletion of circulating IgE antibodies, as well as for the depletion of IgE-bearing cells.
AB - Background: The IgE-mediated activation of effector cells and antigen-presenting cells through the high-affinity receptor for IgE (FcεRI) represents a key pathomechanism in type I allergy and many forms of asthma. Objective: We sought to establish an in vitro molecular model for the interaction of human FcεRI, IgE, and the corresponding allergen and to identify monoclonal anti-human IgE anti-bodies with a therapeutic profile different from previously established anti-IgE antibodies. Methods: Human FcεRI α chain, a human monoclonal allergen-specific IgE antibody (chimeric Bip 1), and the corresponding allergen, the major birch pollen allergen Bet v 1, were produced as recombinant proteins and analyzed by means of circular dichroism and native overlays, respectively. Using this molecular model, as well as negative stain immunoelectron microscopic analysis, and in vitro cultivated human basophils, we characterized mouse anti-human IgE antibodies. Results: We established a molecular model for the interaction of human IgE with FcεRI. Using this molecular model, we identified a nonanaphylactic anti-human IgE antibody fragment (Fab12), which blocked the IgE-FcεRI interaction and reacted with effector cell-bound IgE. Conclusion: Fab12 represents a candidate molecule for therapy of atopy and asthma because it can be used for the depletion of circulating IgE antibodies, as well as for the depletion of IgE-bearing cells.
KW - Allergy
KW - Asthma
KW - Competitor
KW - FcεRI
KW - IgE
KW - Therapy
UR - http://www.scopus.com/inward/record.url?scp=0034827566&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034827566&partnerID=8YFLogxK
U2 - 10.1067/mai.2001.117593
DO - 10.1067/mai.2001.117593
M3 - Article
VL - 108
SP - 409
EP - 416
JO - Journal of Allergy and Clinical Immunology
JF - Journal of Allergy and Clinical Immunology
SN - 0091-6749
IS - 3
ER -